Clinical observation of bevacizumab combined with pemetrexed for patients with re-current metastatic cervical cancer
10.3969/j.issn.1000-8179.2019.02.005
- VernacularTitle:贝伐珠单抗联合培美曲塞治疗复发转移性宫颈癌患者的临床观察
- Author:
Liang LU
1
;
Hanqun ZHANG
;
Hui CAO
;
Zhiyu FENG
;
Jia YUAN
;
Xin LI
;
Yong LI
Author Information
1. 贵州省人民医院肿瘤科(贵阳市550002
- Keywords:
bevacizumab;
pemetrexed;
cervical cancer;
chemotherapy
- From:
Chinese Journal of Clinical Oncology
2019;46(2):83-85
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the short-term efficacy and side effects of bevacizumab combined with pemetrexed for the treat-ment of recurrent and metastatic cervical cancer. Methods: The clinical data of 32 patients with recurrent metastatic cervical cancer admitted to the Department of Oncology, Guizhou Provincial People's Hospital between January 2014 and December 2016 were retro-spectively analyzed. All patients were treated with bevacizumab plus pemetrexed. In the 21-day cycle, chemotherapy was adminis-tered for 4 to 6 cycles. The efficacy and grade of adverse reactions were evaluated. Results: Of the 32 patients with cervical cancer, 0 had complete remission, 7 (21.9%) had partial remission, 19 (59.4%) had stable disease, and 6 (18.7%) had disease progression. The ef-fective rate was 21.9% (7/32) and the disease control rate was 81.3% (26/32). The 32 patients had mild common adverse reactions, which can be tolerated. Conclusions: Bevacizumab combined with pemetrexed has good short-term effects for patients with recurrent and metastatic cervical cancer, and its side effects can be tolerated. The long-term efficacy warrants further study.
